Compositions for the treatment of overactive bladder
AssigneeTheravida, Inc.
InventorMehdi Paborji
Life of this patent
Estimating the term…
Abstract
Disclosed herein are pharmaceutical compositions comprising combinations of tolterodine, an antimuscarinic agent, and pilocarpine, a compound that causes stimulation of salivary glands. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient said pharmaceutical composition.
Claims22
A pharmaceutical composition comprising a therapeutically effective amount of a first compound and a therapeutically effective amount of a second compound, wherein the first compound is tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, and the second compound is pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof,
- wherein the tolterodine and pilocarpine are formulated such that the peak saliva flow time point for pilocarpine occurs at nearly the same time as the lowest saliva flow time point for tolterodine.
A method of treating overactive bladder in a patient comprising
- administering to a patient in need thereof a therapeutically effective amount of a first compound and a therapeutically effective amount of a second compound,
- wherein the first compound is tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, and the second compound is pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof,
- wherein the tolterodine and pilocarpine are administered such that the peak saliva flow time point for pilocarpine occurs at nearly the same time as the lowest saliva flow time point for tolterodine;
- whereby a symptom of overactive bladder is alleviated or ameliorated.
A pharmaceutical composition comprising a dose of tolterodine, or a free base thereof or a pharmaceutically acceptable salt thereof, in the range of between 1 mg to 30 mg, in combination with a dose of pilocarpine, or a free base thereof or a pharmaceutically acceptable salt thereof, in the range of between 1 mg to 30 mg;
- wherein the tolterodine and pilocarpine are formulated such that the peak saliva flow time point for pilocarpine occurs at nearly the same time as the lowest saliva flow time point for tolterodine.
Dependencies are inferred from the claim text.